A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS

This study tests a new oral drug called Prosetin (NRC-2694-A) for people with ALS (also known as Lou Gehrig's disease), a progressive neurological condition that affects movement. The study is evaluating whether the drug is safe and how it behaves in the body. **You may be eligible if...** - You are 18 or older and have a confirmed diagnosis of ALS - Your lung function is above 50% of normal - You are able to swallow liquids to take the study medication - If you take riluzole or other approved ALS medications, your dose has been stable for at least 30 days **You may NOT be eligible if...** - You have significant dementia or another neurological disease besides ALS - You have had episodes of vertigo in the past year or a history of seizures - You have had cancer in the past 5 years (certain exceptions may apply) - You have previously received stem cell or gene therapy for ALS - You are currently in another clinical drug trial Talk to your doctor to see if this trial is right for you.